Exelixis

CompanyUnited StatesFounded 1994

Exelixis develops one asset, in phase 1 (XL309 in BRCA-mutated cancer). Mostly small molecule acting on USP1 and DNA repair; based in the United States, founded in 1994.

1
Asset
Furthest: Phase 1; 4
Trials: 0
Signals

Pipeline

1

XL309
Inhibits USP1.
Phase 1, Small molecule, USP1, DNA repair, BRCA-mutated cancer

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms1
Trials9
Similar companies6

Papers

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
The Lancet. Oncology, 5 Jun 2016

Updated 11 Oct 2026 · 20 sources